Literature DB >> 20441994

The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma.

Bomi Kim1, Jae Kyung Myung, Ja Hee Seo, Chul-Kee Park, Sun Ha Paek, Dong Gyu Kim, Hee-Won Jung, Sung-Hye Park.   

Abstract

Glioblastoma (GBM) is a malignant CNS neoplasm. The prognosis of GBM may be influenced by the molecules of p53/MDM2/p14ARF, RB/p16INK4a, and the EGFR/PTEN/protein kinase B (PKB)/phosphoinositide 3-kinase (PI3K) pathways. We studied the expression status of specific molecular markers in GBMs by immunohistochemistry (IHC) and FISH in correlation with the clinical outcomes. The positivity of EGFR FISH and those of EGFR IHC by pharmDx and Zymed antibodies were 64.9%, 73.5%, and 43.4%, respectively. EGFR pharmDx antibody was more sensitive but less specific than EGFR Zymed antibody. p53 overexpression, MDM2 expression, p16 loss, PTEN loss, PKB and PI3K expression were found in 48.2%, 26.5%, 56.6%, 21.4%, 15.7% and 6.0%, respectively. EGFR IHC and FISH significantly, although not completely, correlated and EGFR and p53 immunoexpression also showed positive correlation. On multivariate survival studies, old age (> or =40 yrs) and bilaterality were independent unfavorable prognosis factors (p<0.05). Stratified by age, resectability and tumor size <5 cm were favorable survival factors in young (40<yrs) and old age groups (> or =40 yrs), respectively. Furthermore, the patients with supratentorial tumor lived longer than the patients with infratentorial tumor (p<0.05). Longer survival (survival length, > or =3 years) was statistically less frequent in the patients in the EGFR FISH-positive group (p=0.031). Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20441994     DOI: 10.1016/j.jns.2010.03.019

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  13 in total

1.  EGFR expression stratifies oligodendroglioma behavior.

Authors:  Craig Horbinski; Jonathan Hobbs; Kathleen Cieply; Sanja Dacic; Ronald L Hamilton
Journal:  Am J Pathol       Date:  2011-08-11       Impact factor: 4.307

2.  Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification?

Authors:  Zoé Pedeutour-Braccini; Fanny Burel-Vandenbos; Catherine Gozé; Coralie Roger; Audrey Bazin; Valérie Costes-Martineau; Hugues Duffau; Valérie Rigau
Journal:  Virchows Arch       Date:  2015-01-21       Impact factor: 4.064

3.  Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.

Authors:  Daniel J Brat; Kenneth Aldape; Julia A Bridge; Peter Canoll; Howard Colman; Meera R Hameed; Brent T Harris; Eyas M Hattab; Jason T Huse; Robert B Jenkins; Dolores H Lopez-Terrada; William C McDonald; Fausto J Rodriguez; Lesley H Souter; Carol Colasacco; Nicole E Thomas; Michelle Hawks Yount; Martin J van den Bent; Arie Perry
Journal:  Arch Pathol Lab Med       Date:  2022-05-01       Impact factor: 5.686

4.  Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.

Authors:  Dayane B Koshiyama; Patrícia Trevisan; Carla Graziadio; Rafael F M Rosa; Bibiana Cunegatto; Juliete Scholl; Valentina O Provenzi; Alexandre P de Sá; Fabiano P Soares; Maíra C Velho; Nelson de A P Filho; Ceres A Oliveira; Paulo R G Zen
Journal:  J Neurooncol       Date:  2017-08-30       Impact factor: 4.130

5.  Complete diagnostics and clinical approach for a female patient with unusual glioblastoma: A case study.

Authors:  Filip Samal; Libor Stanek; Michal Filip; Pavel Haninec; Ales Vícha; Zdenek Musil; Petra Tesarova; Lubos Petruzelka; Drahomira Springer; Milena Kralickova; Milada Kohoutova; Tomas Zima
Journal:  Mol Clin Oncol       Date:  2016-05-10

6.  C-MET overexpression and amplification in gliomas.

Authors:  Yoonjin Kwak; Seong-Ik Kim; Chul-Kee Park; Sun Ha Paek; Soon-Tae Lee; Sung-Hye Park
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

7.  Distinct genetic alterations in pediatric glioblastomas.

Authors:  Sun-ju Byeon; Jae Kyung Myung; Se Hoon Kim; Seung-Ki Kim; Ji Hoon Phi; Sung-Hye Park
Journal:  Childs Nerv Syst       Date:  2012-05-09       Impact factor: 1.475

8.  Emerging biomarkers in glioblastoma.

Authors:  Mairéad G McNamara; Solmaz Sahebjam; Warren P Mason
Journal:  Cancers (Basel)       Date:  2013-08-22       Impact factor: 6.639

9.  Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.

Authors:  Katrin Höland; Danielle Boller; Christian Hagel; Silvia Dolski; András Treszl; Olivier E Pardo; Paulina Cwiek; Fabiana Salm; Zaira Leni; Peter R Shepherd; Beata Styp-Rekowska; Valentin Djonov; André O von Bueren; Karl Frei; Alexandre Arcaro
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

10.  Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma.

Authors:  Chul-Kee Park; Se-Hoon Lee; Ji Young Kim; Ja Eun Kim; Tae Min Kim; Soon-Tae Lee; Seung Hong Choi; Sung-Hye Park; Il Han Kim
Journal:  Oncotarget       Date:  2014-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.